Change language dansk English suomi svenska

Generate Estimates Confirm Cancel Hide empty rows Show hidden rows DummyText

JEMO-PHARM A/S

Quicksearch from your own companies XBRLDenmark Analyst: XBRLDenmark

Loading... Loading... Loading... Loading...   Loading...

1000.0 Bankruptcy Risk  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Bankruptcy risk for industry   7.1% 7.1% 7.1% 7.1% 7.1% 7.1% 7.1% 7.1%   Bankruptcy risk   1.8% 5.0% 3.7% 1.7% 2.5% 1.9% 7.4% 7.4%   Credit score (0-100)   72 45 51 71 62 65 10 10   Credit rating   BBB BB BB BBB BBB BBB BB BB   Credit limit (kDKK)   2.0 -0.0 0.0 3.8 0.0 0.7 -0.0 -0.0   How are these values calculated?   View the automatically generated explanation of bankruptcy risk 1000.0 Income statement (kDKK)  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Net sales   0 0 0 0 0 0 0 0   Gross profit   9,753 5,906 8,608 11,517 10,078 12,326 0.0 0.0   EBITDA   3,573 -2,859 614 3,509 2,737 3,756 0.0 0.0   EBIT   1,924 -4,489 -971 2,035 1,132 1,814 0.0 0.0   Pre-tax profit (PTP)   268.0 -7,307.0 -3,332.0 286.0 -1,054.0 -452.0 0.0 0.0   Net earnings   23.0 -6,078.0 -2,809.0 166.0 -930.0 -560.0 0.0 0.0   Pre-tax profit without non-rec. items   268 -7,307 -3,332 286 -1,054 -452 0.0 0.0     See the entire income statement 1000.0 Balance sheet (kDKK)  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Tangible assets total   10,308 9,322 8,097 8,134 7,284 6,494 0.0 0.0   Shareholders equity total   2,561 -3,517 400 566 -364 -160 -560 -560   Interest-bearing liabilities   31,214 37,184 30,293 29,884 31,806 36,988 6,485 6,485   Balance sheet total (assets)   38,790 39,246 39,680 41,053 42,226 42,630 5,925 5,925   Net Debt   31,049 36,647 29,418 29,164 31,667 36,231 6,485 6,485     See the entire balance sheet 1000.0 Volume  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Net sales   0 0 0 0 0 0 0 0   Net sales growth   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Gross profit   9,753 5,906 8,608 11,517 10,078 12,326 0.0 0.0   Gross profit growth   7.8% -39.4% 45.8% 33.8% -12.5% 22.3% -100.0% 0.0%   Employees   20 25 24 28 29 32 0 0   Employee growth %   17.6% 25.0% -4.0% 16.7% 3.6% 10.3% -100.0% 0.0%   Employee expenses   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Balance sheet total (assets)   38,790 39,246 39,680 41,053 42,226 42,630 5,925 5,925   Balance sheet change%   36.6% 1.2% 1.1% 3.5% 2.9% 1.0% -86.1% 0.0%   Added value   3,573.0 -2,859.0 614.0 3,509.0 2,606.0 3,756.0 0.0 0.0   Added value %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Investments   -828 -2,565 -1,354 414 -2,373 -2,002 -6,494 0   Net sales trend   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   EBIT trend   3.0 -1.0 -2.0 1.0 2.0 3.0 0.0 0.0   1000.0 Profitability  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A EBITDA %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   EBIT %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   EBIT to gross profit (%)   19.7% -76.0% -11.3% 17.7% 11.2% 14.7% 0.0% 0.0%   Net Earnings %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Profit before depreciation and extraordinary items %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Pre tax profit less extraordinaries %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   ROA %   3.4% -15.1% -4.0% 3.3% 0.3% 2.4% 0.0% 0.0%   ROI %   3.8% -16.8% -4.5% 3.9% 0.3% 2.7% 0.0% 0.0%   ROE %   0.9% -29.1% -14.2% 34.4% -4.3% -1.3% 0.0% 0.0%   1000.0 Solidity  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Equity ratio %   6.6% -8.2% 1.0% 1.4% -0.9% -0.4% -8.6% -8.6%   Relative indebtedness %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Relative net indebtedness %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Net int. bear. debt to EBITDA, %   869.0% -1,281.8% 4,791.2% 831.1% 1,157.0% 964.6% 0.0% 0.0%   Gearing %   1,218.8% -1,057.3% 7,573.3% 5,279.9% -8,737.9% -23,117.5% -1,158.0% -1,158.0%   Net interest   0 0 0 0 0 0 0 0   Financing costs %   3.2% 3.4% 5.0% 3.5% 3.8% 4.2% 0.0% 0.0%   1000.0 Liquidity  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Quick Ratio   0.4 0.4 0.4 0.4 0.4 0.4 0.0 0.0   Current Ratio   0.7 0.7 0.8 0.8 0.8 0.7 0.0 0.0   Cash and cash equivalent   165.0 537.0 875.0 720.0 139.0 757.0 0.0 0.0   1000.0 Capital use efficiency  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Trade debtors turnover (days)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Trade creditors turnover (days)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Current assets / Net sales %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Net working capital   -9,310.0 -13,077.0 -7,533.0 -8,565.0 -7,495.0 -12,484.0 -3,242.5 -3,242.5   Net working capital %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   1000.0 Employee efficiency  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Net sales / employee   0 0 0 0 0 0 0 0   Added value / employee   179 -114 26 125 90 117 0 0   Employee expenses / employee   0 0 0 0 0 0 0 0   EBITDA / employee   179 -114 26 125 94 117 0 0   EBIT / employee   96 -180 -40 73 39 57 0 0   Net earnings / employee   1 -243 -117 6 -32 -18 0 0